COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical, Inc. (COLL) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Growth (D+). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B (3.2) | D+ (1.7) | B+ (3.7) | C (2.2) | C+ (2.6) | C+ (2.7) |
| 2026-11-04 | B (3.2) | C- (1.9) | B+ (3.7) | D (1.5) | C+ (2.7) | C+ (2.6) |
| 2026-10-28 | B (3.2) | C- (1.9) | B+ (3.7) | D (1.4) | C+ (2.7) | C+ (2.6) |
| 2026-10-21 | B (3.2) | C- (1.9) | B+ (3.7) | D (1.5) | C+ (2.6) | C+ (2.6) |
| 2026-10-14 | B (3.2) | D+ (1.8) | B+ (3.7) | D (1.3) | C+ (2.6) | C+ (2.5) |